He Yingying, Xie Fei, He Tianli, Zhou Zhou, Chen Zhaohong, Jiang Lixing, Hu Wei
Oncology Department, Deyang People's Hospital, Deyang, China.
Radiotherapy Oncology Department, Changxing Campus (Changxing People's Hospital), Second Affiliated Hospital of Zhejiang University School of Medicine, Changxing, China.
Front Oncol. 2025 Mar 10;15:1367346. doi: 10.3389/fonc.2025.1367346. eCollection 2025.
Intramedullary spinal cord metastases (ISCMs) are rare in clinical practice and their presentation is usually an unfavorable sign with a median overall survival (mOS) of 3-4 months after diagnosis. Due to their rarity, heterogeneity and rapid progression, clinicians have few satisfactory guidelines or optimal management for ISCMs. Herein, we share a clinical experience of intensity-modulated radiotherapy (IMRT) combined with immunotherapy (IO) for ISCMs from lung adenocarcinoma (LUAD) that achieved a relatively high quality of life for 10 months, which has not been previously reported.
脊髓髓内转移瘤（ISCMs）在临床实践中较为罕见，其出现通常是一个不良征兆，诊断后的中位总生存期（mOS）为3至4个月。由于其罕见性、异质性和快速进展，临床医生对于ISCMs几乎没有令人满意的指南或最佳治疗方案。在此，我们分享一例肺腺癌（LUAD）脊髓髓内转移瘤采用调强放射治疗（IMRT）联合免疫治疗（IO）的临床经验，该患者获得了相对较高的生活质量，持续了10个月，此前尚未有过相关报道。
